Overview

Study of Clofarabine & Cytosine Arabinoside Therapy for Older Adults With Acute Myeloid Leukemia

Status:
Completed
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the recommended phase II dose of clofarabine when administered in combination with standard dose Ara-C to older (>=60 years of age) patients with newly diagnosed acute myeloid leukemia (AML).
Phase:
Phase 1
Details
Lead Sponsor:
University of Alabama at Birmingham
Collaborator:
Genzyme, a Sanofi Company
Treatments:
Clofarabine
Cytarabine